Sign in
CBAY Stock Price, Chart, Stats & News
CymaBay Therapeutics, Inc.
Save
CymaBay Therapeutics, Inc. (CBAY) does not currently pay a dividend.
3.73B
Market cap
–
Current P/E
–
Forward P/E
CBAY chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 97.81% |
Operating margin | -327.23% |
Pretax margin | -339.10% |
Net margin | -339.10% |
Effective tax rate | – |
ROA | -24.24% |
ROE | -64.17% |
D/E | 0.39x |
Interest coverage ratio | -5.37x |
CBAY valuation
P/E | – |
P/S | 119.98x |
P/B | 11.80x |
P/CF | -47.56x |
P/FCF | -51.09x |
P/OCF | -47.56x |
PEG | -0.33x |
EV multiple | -44.55x |
About
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH).
Similar securities
Based on sector and market capitalization
Report issue